

Study Number	AHOD1331			
NCT #	NCT02166463			
Dataset #	NCT02166463-D1			
PMID #	36322844			
<p>Comments: Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).</p>				
Variable Number	Variable Name	Type	Label	Notes
1	USI_PatientID	Character	Patient ID	
2	SiteNumber	Numeric	Randomly assigned National Cancer Institute's site code	
3	Inelig	Numeric	Indicates patient is not eligible for study (1=Not eligible)	
4	FU_MONTHS	Numeric	Follow-up time (months)	
5	EFS	Numeric	Event Free Survival (EFS) event includes progression/relapse, second malignancy (SMN), and death (1=Event, 0=censored)	
6	FUTIME_EFS_M	Numeric	Event free survival time (months)	
7	Tx	Character	Treatment	
8	RT	Character	Did patient receive radiation therapy	
9	OS	Numeric	Overall survival (OS) event (1=Death, 0=censored)	
10	FUTIME_OS_M	Numeric	Overall survival time (months)	
11	Sex	Character	Sex	
12	Race_Ethnic	Character	Race and Ethnic group (NHW=Non-Hispanic White, NHB= Non-Hispanic Black)	
13	Stratum	Character	Stratum	
14	LMA	Character	Indicates presence of Large Mediastinal Adenopathy	
15	Bsymptoms	Numeric	B symptoms were defined as weight loss, night sweats, and fever (1=Yes, 0=No, 99=Unknown)	
16	AGE	Numeric	Age at time of enrollment (years)	
17	Agegroup12	Numeric	Age>=12 years at time of enrollment (1=Yes, 0=No)	
18	Event_type	Numeric	First EFS event type: (2=progression/relapse, 3=SMN, 4=death, 0=censored)	

Study Number	AHOD1331		
NCT #	NCT02166463		
Dataset #	NCT02166463-D1		
PMID #	36322844		
<p>Comments: Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).</p>			
19	RESPONSE	Character	Response Type at the end of cycle 2 (SRL=slow-responding lesions, RRL=rapid-responding lesions)
20	SRL_CM	Numeric	Slowly Responding Lesion at the end of cycle 2, Complete Metabolic Response at the end of cycle 5 (1=Yes, 0=No)
21	Ineval	Numeric	Indicates patient is not evaluable for analyses (1=Not evaluable)
22	Pet2_tx	Character	FDG-PET Scan results at the end of cycle 2 with treatment group
23	event_days_3yr	Numeric	3-year Event free survival time (days)
24	EFS_3yr	Numeric	3-year EFS event (1=Event, 0=censored)
25	RRL_LMA	Numeric	Rapidly Responding Lesion at the end of cycle 2, has Large Mediastinal Adenopathy (1=Yes, 0=No)
26	SRL	Numeric	Slowly Responding Lesion at the end of cycle 2 (1=Yes, 0=No)
27	SRL_IMR	Numeric	Slowly Responding Lesion at the end of cycle 2, Incomplete Metabolic Response at the end of cycle 5 (1=Yes, 0=No)
28	TOX_3	Character	Grade 3 or higher Adverse Events reported during treatment
29	TOX_FN	Character	Grade 3 or higher Febrile neutropenia reported during treatment
30	TOX_MO	Character	Grade 3 or higher Mucositis or oral adverse event reported during treatment
31	TOX_ET	Character	Grade 3 or higher Enterocolitis or typhlitis reported during treatment
32	TOX_AL	Character	Grade 3 or higher Allergic reaction or anaphylaxis reported during treatment
33	TOX_SE	Character	Grade 3 or higher sepsis reported during treatment
34	TOX_IN	Character	Grade 3 or higher Infusion-related reaction reported during treatment

Study Number	AHOD1331			
NCT #	NCT02166463			
Dataset #	NCT02166463-D1			
PMID #	36322844			
<p>Comments: Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).</p>				
35	TOX_VA	Character	Grade 3 or higher Vascular-access complication reported during treatment	
36	TOX_ALT	Character	Grade 3 or higher Elevated alanine aminotransferase level reported during treatment	
37	TOX_TH	Character	Grade 3 or higher Thromboembolic event reported during treatment	
38	TOX_PA	Character	Grade 3 or higher Pancreatitis reported during treatment	
39	TOX_PN	Character	Grade 3 or higher pneumonitis reported during treatment	
40	TOX_CO	Character	Grade 3 or higher Constipation reported during treatment	
41	Tox_Neuropathy_3	Numeric	Grade 3 or higher neuropathy reported during treatment (1=Yes, 0=No)	
42	Tox_Neuropathy_2	Numeric	Grade 2 or higher neuropathy reported during treatment (1=Yes, 0=No)	
43	mdoserpdall	Character	Any dose modifications or additions/omissions to protocol treatment?	
44	Brentuximaball	Numeric	Were there any Brentuximab Vedotin dose modifications or additions/omissions to protocol treatment? (1=Yes, 0=No)	
45	Vincristineall	Numeric	Were there any Vincristine dose modifications or additions/omissions to protocol treatment? (1=Yes, 0=No)	
46	Otherall	Numeric	Were there any other dose modifications or additions/omissions to protocol treatment? (1=Yes, 0=No)	
47	Stage	Character	Stage	
48	Histology	Character	Histology	
49	Race_new	Character	Race: Non-hispanic white vs Other	Collapsed version used in Figure 2
50	Bone_marrow	Character	Bone marrow involvement	
51	Bulk	Numeric	Bulk tumor (1=Yes, 0=No)	

Study Number	AHOD1331			
NCT #	NCT02166463			
Dataset #	NCT02166463-D1			
PMID #	36322844			
<p>Comments: Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).</p>				
52	INELIG_REASON	Character	Ineligible reason	
53	Not_Evaluable_Reason	Character	Not Evaluable Reason	
54	RRL_NOLMA	Numeric	Rapidly Responding Lesion at the end of cycle 2, No Large Mediastinal Adenopathy (1=Yes, 0=No)	
55	SRL_LMA	Numeric	Slowly Responding Lesion at the end of cycle 2, has Large Mediastinal Adenopathy (1=Yes, 0=No)	
56	EFS_DATACUTOFF_RP1	Numeric	EFS events March 16, 2015 - December 31, 2017 (1=Yes)	
57	EFS_DATACUTOFF_RP2	Numeric	EFS events January 1 - December 31, 2018 (1=Yes)	
58	EFS_DATACUTOFF_RP3	Numeric	EFS events January 1 - December 31, 2019 (1=Yes)	
59	EFS_DATACUTOFF_RP4	Numeric	EFS events January 1 - December 31, 2020 (1=Yes)	
60	EFS_DATACUTOFF_RP5	Numeric	EFS events January 1 - December 31, 2021 (1=Yes)	The 6-month reporting periods listed in Table S3 are not provided due to deidentification.
61	RACE_DETAILED_LEVEL	Character	More detailed level race data	